TriLink BioTechnologies and Lonza Partner to Accelerate mRNA-Based Therapies and Vaccines with CleanCap Technology

TriLink BioTechnologies, a subsidiary of Maravai LifeSciences, has struck a non-exclusive License and Supply Agreement with Lonza, a leading global development and manufacturing partner to the pharmaceutical, biotechnology, and nutrition industries. The agreement aims to increase access to CleanCap mRNA capping technologies as demand for mRNA continues to rise.

Under the terms of the agreement, TriLink will provide Lonza with its patented CleanCap M6, CleanCap AG 3’OMe, CleanCap AG, and CleanCap AU cap analogs. These will be used in Lonza’s global mRNA development and manufacturing services, ranging from pre-clinical studies to Phase III programs.

CleanCap technology offers a streamlined solution with over 95% capping efficiency, simplifying mRNA production processes in comparison to traditional capping methods. This innovation has the potential to accelerate programs from discovery to clinical trials by enhancing mRNA function, optimizing manufacturing processes, and maximizing capped material yield.

Drew Burch, President of Nucleic Acid Production at TriLink expressed his excitement about the partnership stating “CleanCap technology is accelerating programs from discovery to the clinic via improved mRNA function, streamlined manufacturing, and maximized capped material yield.” The collaboration with Lonza is expected to further support the advancement of mRNA technologies.

TriLink first introduced its CleanCap capping technology in 2017 which is now widely used in the production of approved mRNA and saRNA vaccines. In May 2023, TriLink launched its latest CleanCap analogue CleanCap M6 which has demonstrated a significant increase in mRNA expression compared to enzymatic capping methods. This innovative technology continues to drive advancements in mRNA-based therapies and vaccines.